

## Participation in PSCI (Pharmaceutical Supply Chain Initiative)

---

**OSAKA, Japan, December 5, 2017** - Shionogi & Co., Ltd. (hereafter "Shionogi") announced its participation in PSCI (Pharmaceutical Supply Chain Initiative), which is a non-profit organization aiming to promote the CSR procurement in the pharmaceutical and healthcare industry. Shionogi is the second Japanese pharmaceutical company as a member of PSCI.

(PSCI website : <https://pscinitiative.org/home>)

PSCI was established in US in 2006. More than 20 companies all over the world are members of PSCI. PSCI has set its principles, offering the audit tools such as audit guidelines and questionnaires, and the audit education system. Also, PSCI contribute to the efficiency of members' audit procedure.

In its principles, not only environment, safety and health but also rights of labors, ethics and related management systems are listed. Shionogi agrees with its principles and also requires the agreement by our suppliers, based on this mutual agreement Shionogi promotes activities of CSR supply chain management in the whole value chain.

Shionogi has its vision, "Grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improves healthcare" striving to continue to be a company needed from society at large. Shionogi more promotes activities of CSR supply chain management in the whole value chain. Through these activities, Shionogi strives to create our company's value sustainably with all our stakeholders.

# PSCI

PHARMACEUTICAL SUPPLY CHAIN INITIATIVE

**About Shionogi**

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders. For over 50 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives. In addition, Shionogi is engaged in new research areas, such as obesity/geriatric metabolic disease and oncology/immunology. Contributing to the health and quality of life of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit [www.shionogi.co.jp/en/](http://www.shionogi.co.jp/en/). For more information on Shionogi Inc., the U.S.-based subsidiary of Shionogi & Co., Ltd., headquartered in Florham Park, NJ, USA, please visit [www.shionogi.com](http://www.shionogi.com). For more information on Shionogi Ltd., the UK-based subsidiary of Shionogi & Co. Ltd., headquartered in London, England, please visit [www.shionogi.eu](http://www.shionogi.eu).

**Forward Looking Statement**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

**Contacts:**

Corporate Communications, Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596